A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans

Mar 26, 2025Molecular metabolism

Once-daily triple hormone receptor drug (NN1706) reduces body weight in rodents, monkeys, and humans

AI simplified

GLP-1 TherapiesGLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Daily subcutaneous NN1706 treatment resulted in substantial body weight loss in human participants with overweight or obesity.

  • NN1706 is a tri-agonist targeting GLP-1R and GIPR with lower potency at the glucagon receptor.
  • In preclinical studies, NN1706 led to significant body weight reductions and improved glycemic control in obese mice, rats, and non-human primates.
  • The weight loss effect in humans was observed in a dose-dependent manner.
  • Increased heart rate was noted across treatment cohorts, which may hinder further clinical development.

AI simplified

Full Text

Full text is available at the source.
View full text (XML) ↗View full text ↗

Related papers

Dec '18
Improved GIP-like drugs reduce body weight in mice by activating, not blocking, GIP receptors
top 5% journal
cited by 206 papers
research support, non-u.s. gov't
Nov '24
Loss of a specific signaling in inhibitory brain cells increases weight loss caused by GLP-1 receptor drugs
top 5% journal
cited by 18 papers
journal article
Jul '21
Long-Lasting Modified Frog GLP-1 Compounds That Activate Both GLP-1 and Glucagon Receptors to Treat Metabolic Disease
top 20% journal
cited by 9 papers
research support, non-u.s. gov't
Jul '18
Combined Effects of Glucagon and GLP-1 Drugs in Obese Diabetic Monkeys
top 10% journal
cited by 22 papers
research support, non-u.s. gov't
Mar '24
Loss of GIP receptor in leptin receptor cells reduces glucose control by GIP and GIP-GLP-1 combination without changing body weight or food intake in mice
top 5% journal
cited by 11 papers
research support, non-u.s. gov't
Jun '17
A new GIP-like drug, ZP4165, boosts weight loss and blood sugar control caused by GLP-1 in rodents
cited by 113 papers
comparative study
Jun '20
Fast identification of a new drug that activates two hormone receptors to improve blood sugar control and reduce weight in rodents
cited by 6 papers
journal article
Jun '18
Activating both GLP-1 and glucagon receptors helps control body weight and blood sugar in mice and primates
top 5% journal
cited by 33 papers
comparative study
Jul '16
Strong weight loss and metabolism improvements from a drug targeting two hormone receptors in rodents and monkeys
top 5% journal
cited by 224 papers
journal article

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #35
Semaglutide linked to 2.5x higher risk of sudden vision loss
3 days ago7 studies
issue #34
Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial
1 week ago7 studies
issue #33
Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes
2 weeks ago7 studies
issue #32
60% of weight lost on GLP-1 drugs returns within a year of stopping
3 weeks ago7 studies
issue #31
Semaglutide linked to 54% lower risk of new sleep apnea cases in 1.25 million patients
4 weeks ago7 studies
issue #30
Tirzepatide beats semaglutide for heart protection in 70,672 non-diabetic adults with obesity
5 weeks ago7 studies
issue #29
Stopping GLP-1 drugs before endoscopy cuts stomach content risk from 25% to 3%
6 weeks ago7 studies
issue #28
Semaglutide linked to 74-fold higher risk of vision-threatening eye condition
7 weeks ago3 studies
issue #27
GLP-1 drugs linked to 18% lower risk of substance use disorders in 524,817 veterans
8 weeks ago7 studies
issue #26
86.5% of patients on semaglutide or tirzepatide lost at least 5% of body weight at 6 months in Medicaid study
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief